Acrivon’s ACR-7280 shows complete tumor regression in AML mouse models
ACRV•Acrivon Therapeutics said its oral CDK11 inhibitor ACR-7280 produced complete tumor regression in aggressive acute myeloid leukemia mouse models. The company is conducting IND-enabling studies and expects to file with the FDA in the first half of 2027.
1. Preclinical results
Acrivon Therapeutics said preclinical testing of ACR-7280 showed complete tumor regression in aggressive acute myeloid leukemia mouse models. The company also reported strong synergy with venetoclax and menin inhibitors across several leukemia models.
2. Development plans
IND-enabling studies are underway for the oral CDK11 inhibitor, which was selected using Acrivon’s AP3 drug discovery platform. Acrivon expects to file an investigational new drug application with the FDA in the first half of 2027, initially focusing development on acute myeloid leukemia as a single agent and in combinations.
